1[1]Haiyan Wang,Luxia Zhang,Ji Cheng Lv.Prevention of the progression of kidney disease:practice in China[J].Kidney Int,2005;67(94 Suppl):63-67
2[2]Zimmermann J,herrlinger S,Pruy A,et al.Inflammation enhances cardiovascular risk and mortality in hemodialysis patients [J].Kidney Int,1999;55:648-658
3[3]Anderson MM,Hazen SL,Hsu FF,et al.Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxyamino acids into glycolaldehyde,2-hydroxypropanal,and acrolein:a machanism for the generation of highly reactive alphal-lydroxy and α,β-unsaturated aldehydes by phagocytes at sites of inflammation[J].J Clin Invest,1997;99:424-432
4[4]Kaysen GA.Hyperlipidemia of chronic renal failure [J].Blood Purif,1994;12:60-67
6[6]Manns BJ,Burgess ED,hyndman ME,et al.hyperhomocyst (e)inemia and the prevalence of athersclerotic vascular disease in patients with endstage renal disease[J].Am J Kidney Dis,1999;34:669-677
7[7]Hosoya N,Sakai K.Backdiffusion rather than backfiltration enhances endotoxin transport through highly permeable dialysis membrance [J].Asaio T Rans,1999;36:M311-M313
8[8]Vanholder R,Ringoir S,Dhondt A,et al.Phagocytosis in uremic and hemodialysis patients:a prospective and cross sectional study[J].Kidney Int,1999;39:320-327
3Kishida M, Urakaze M, Takata M, et al. PGE1 inhibits the expression of PAI-1 mRNA induced by TNF-alpha in human mesangial cells [J]. Exp Clin Endocrinol Diabetes, 2005, 113 (7) : 365-371.
4Tian J, Chen JH, Li Q, et al. Lipid peroxidation in IgA nephropathy and the effect of lipoprostaglandin E1 [ J ]. J Nephrol, 2005, 18 (3): 243-248.
5Fang W, Li H, Zhou L, et al. Effect of prostaglandin E1 on TNF- induced vascular inflammation in human umbilical vein endothelial cells[J]. Can J Physiol Pharmacol, 2010, 88 (5) : 576-583.
6Sun D, Liu CX, Ma YY, et al. Protective effect of prostaglandin E1 on renal microvascular injury in rats of acute aristolochic acid nephropathy[J]. Ren Fail, 2011, 33 (2): 225-232.
7Zhong WQ, Liu GX, Yang YM, et al. Clinical effect of treatment with lipoprostaglandin E1 on the patients with chronic glomerulonephritis[J]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2004, 16 (5) : 292-294.
8Schomig M, Eisenhandt A, Ritz E. The microinflammatory state ofuremia[J].BloodPurif, 2000, 18 (4) : 327-332.
9KrasniakA, Drozdz M, Pasowicz M, et al. Influence ofmicroin- ftammation and oxidative stress on atherosclerosis progression and calcifications in cardiovascular system of hemodialyzed patients during two years follow-up [J]. Przegl Lek, 2007, 64 ( 3 ) : 140-147.
